The Latest
-
5 novel immuno-oncology targets to know before ASCO
Following checkpoint inhibitors is a tough act, but biopharma is hard at work with agents that could shut down other mechanisms cancer cells use to escape immune response.
-
ICER sees current DMD therapies as too pricey, but notes data limitations
Though evidence supporting Sarepta's eteplirsen and golodirsen and PTC's deflazacort "remains sparse," ICER expects all three drugs wouldn't hit certain cost-effectiveness thresholds.
-
WuXi Biologics building dedicated facility to supply 'global vaccine leader'
Though the Chinese company didn't name its latest partner, it did say the pair have in place a 20-year manufacturing contract worth more than $3 billion.
-
No news is bad news for Tocagen
A brain cancer trial of the biotech's combination therapy will continue to final analysis, but investors predict failure as the stock fell to a record low.
-
The NASH dash runs into some early hurdles
In a trio of articles, BioPharma Dive explored the key problems the NASH field faces and what's being done to solve them.
-
Lilly drug scores in Phase 2 Crohn's study
After 12 weeks of treatment, three doses of Lilly's mirikizumab beat placebo on the study's primary endpoint, setting it up for late-stage testing.
-
UniQure snags patents on Huntington's gene therapy as it preps for the clinic
The biotech aims to start a Phase 1/2 study in the second half of 2019 for the experimental gene therapy.
-
Merck puts $1B more into oncology, with kidney cancer a focus
Acquiring Peloton Therapeutics hands Merck a small molecule medicine headed for a Phase 3 renal cell carcinoma trial later this year.
-
Array gets a win in colorectal cancer
Data for the biotech's triple combination missed expectations, but investors drove shares up to a near record high.
-
Deep DiveNo one knows the size of the NASH market
Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.
-
Verily lures major pharmas with promise of speedier clinical research
Pfizer, Novartis, Sanofi and Otsuka will work with Verily on studies planned for the coming years, growing the list of industry partners for the Alphabet unit.
-
ICER seeks to make drug price research more accessible
Pharmas and payers use ICER's work to inform their approach on pricing and coverage, making the group a key voice in the debate over drug value.
-
Deep DiveOn the path to patients, NASH drugs may hit a payer roadblock
Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.
-
BioCryst meets late-stage study goal, but falls short of competition
The biotech's stock tumbled 50% when markets opened Tuesday, as BioCryst's Phase 3 results failed to stack up to rival therapies.
-
Long-term heart data reassures for Medicines Co.
Inclisiran maintained cholesterol-lowering benefit with fewer side effects than competing Amgen and Sanofi/Regeneron products.
-
UK charity sells Keytruda rights for $1.3B
A 2007 deal promised Lifearc royalty payments on the immunotherapy, which went on to become a multibillion-dollar product for Merck.
-
Deep DiveWill a big needle burst the NASH bubble?
With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market.
-
AbbVie brain cancer drug fails late-stage study in another oncology setback
An interim review found the glioblastoma drug didn't improve survival, leading the biotech to end the trial early and halt enrollment for other studies.
-
Biotech in the spotlight at ASCO as pharma takes back seat
Few major data sets are expected from immunotherapy leaders like Merck, Roche and Bristol-Myers. Instead, studies by Amgen, Macrogenics, Blueprint and Seattle Genetics are drawing attention.
-
Gilead CEO pressured on PrEP pricing at House hearing
Critics of Gilead contend it had little to do with the research behind Truvada's use as a preventive therapy — a charge CEO Daniel O'Day rebutted Thursday.
-
Medicare decides against tighter management of HIV drugs
A finalized regulation codifies step therapy and prior authorization practices in five of the Medicare Part D "protected" drug classes, but spares HIV.
-
FDA schedules Aimmune's peanut allergy drug for September expert review
Set to convene earlier than analysts had expected, the advisory committee will discuss what would be the first-ever drug approval for a food allergy.
-
Breast cancer survival data buoys Macrogenics and Puma
Macrogenics touts signs of an overall survival benefit over Herceptin for margetuximab, while Puma's new Nerlynx study points to a delay in progression, for a price.
-
Deep DivePharma, late to digital game, rushes to catch up
In the past two years, six of the largest pharmas appointed chief digital or information officers to top management for the first time, a signal of growing industry interest in revamping how it does business.
-
Thermo Fisher to buy GSK drug plant in Ireland
GSK will receive about $100 million from Thermo for the site, which makes API for drugs that treat conditions like depression and Parkinson's disease.
